RecruitingNCT06640348

Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer

Sponsor

Anhui Provincial Hospital

Enrollment

70 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer, Epithelial

Summary

This project is an open, single-center, prospective study aimed at developing high-sensitivity, high-specificity enrichment SERS chips using femtosecond laser processing technology. It involves extracting information from blood samples of ovarian cancer patients and normal controls, specifically identifying cancer and non-cancer signals. The study will construct a statistical algorithm model for the early diagnosis of ovarian cancer, enabling early identification and intervention for ovarian cancer patients.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new blood-based diagnostic tool that may help detect ovarian cancer earlier and more accurately by analyzing substances in the blood using a highly sensitive laser-based technology. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with ovarian cancer (various types), OR you are having surgery for a non-cancerous (benign) condition - You are willing to provide a blood sample - Your general health is reasonably good (able to carry out normal activity) **You may NOT be eligible if...** - You have serious uncontrolled health conditions (heart disease, active infections, mental illness affecting consent) - You have received a blood transfusion within the past 4 weeks - You are pregnant, breastfeeding, or planning to become pregnant - You have a history of other cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.